Quick Answer
Definium Therapeutics, Inc. reported Stockholders Equity of $332.33 million for fiscal year 2025.
Definium Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $332.33M | +37.6% |
| 2024 | $241.45M | +209.0% |
| 2023 | $78.13M | -48.2% |
| 2022 | $150.92M | -0.5% |
| 2021 | $151.66M | +99.9% |
| 2020 | $75.87M | +1488.5% |
| 2019 | $4.78M | — |
| 2019 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $130.60M | -50.2% | -29.6% |
| June 30, 2025 | $185.40M | -8.2% | -16.8% |
| March 31, 2025 | $222.81M | +13.6% | -7.7% |
| December 31, 2024 | $241.45M | +209.0% | -7.9% |
| September 30, 2024 | $262.19M | +173.2% | +29.8% |
| June 30, 2024 | $202.05M | +90.7% | +3.1% |
| March 31, 2024 | $196.06M | +50.4% | +150.9% |
| December 31, 2023 | $78.13M | -48.2% | -18.6% |
- Definium Therapeutics, Inc. showed an increase of +37.6% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Definium Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: